CytoMed Therapeutics (GDTC) Competitors $2.17 -0.08 (-3.56%) As of 03:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends GDTC vs. BMEA, SAVA, NBTX, XBIT, TSVT, IFRX, LPTX, TELO, PEPG, and MNPRShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Biomea Fusion (BMEA), Cassava Sciences (SAVA), Nanobiotix (NBTX), XBiotech (XBIT), 2seventy bio (TSVT), InflaRx (IFRX), Leap Therapeutics (LPTX), Telomir Pharmaceuticals (TELO), PepGen (PEPG), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical preparations" industry. CytoMed Therapeutics vs. Biomea Fusion Cassava Sciences Nanobiotix XBiotech 2seventy bio InflaRx Leap Therapeutics Telomir Pharmaceuticals PepGen Monopar Therapeutics CytoMed Therapeutics (NASDAQ:GDTC) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation. Do analysts rate GDTC or BMEA? CytoMed Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 128.31%. Biomea Fusion has a consensus target price of $39.36, indicating a potential upside of 862.44%. Given Biomea Fusion's higher possible upside, analysts plainly believe Biomea Fusion is more favorable than CytoMed Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, GDTC or BMEA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytoMed TherapeuticsN/AN/A-$3.13MN/AN/ABiomea FusionN/AN/A-$117.25M-$4.01-1.02 Does the MarketBeat Community prefer GDTC or BMEA? Biomea Fusion received 54 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 69.05% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformCytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo VotesBiomea FusionOutperform Votes5869.05% Underperform Votes2630.95% Which has more volatility & risk, GDTC or BMEA? CytoMed Therapeutics has a beta of -0.85, indicating that its stock price is 185% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.35, indicating that its stock price is 135% less volatile than the S&P 500. Do institutionals & insiders have more ownership in GDTC or BMEA? 0.0% of CytoMed Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer GDTC or BMEA? In the previous week, Biomea Fusion had 10 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 12 mentions for Biomea Fusion and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.43 beat Biomea Fusion's score of 0.37 indicating that CytoMed Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CytoMed Therapeutics Neutral Biomea Fusion Neutral Is GDTC or BMEA more profitable? CytoMed Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets CytoMed TherapeuticsN/A N/A N/A Biomea Fusion N/A -118.90%-93.66% SummaryBiomea Fusion beats CytoMed Therapeutics on 8 of the 13 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.96M$6.57B$5.28B$8.98BDividend YieldN/A2.91%5.07%4.00%P/E RatioN/A10.2889.3817.21Price / SalesN/A180.251,151.72127.87Price / CashN/A57.6743.2137.77Price / Book2.814.945.125.00Net Income-$3.13M$153.99M$122.18M$228.48M7 Day Performance-4.37%-4.49%-2.40%-0.77%1 Month Performance-19.35%-2.58%-0.54%1.22%1 Year Performance-46.97%-3.21%24.22%16.13% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics1.6896 of 5 stars$2.17-3.6%$5.00+130.4%-45.5%$23.74MN/A0.00N/AShort Interest ↑BMEABiomea Fusion2.8765 of 5 stars$3.92+5.1%$39.36+904.2%-72.7%$142.06MN/A-0.9850Analyst ForecastPositive NewsSAVACassava Sciences4.3729 of 5 stars$2.94+1.7%$111.50+3,692.5%-90.1%$141.44MN/A-2.1330NBTXNanobiotix3.1954 of 5 stars$2.99-0.3%$12.00+301.3%-63.4%$140.93M$36.22M0.00100Short Interest ↓Positive NewsGap UpXBITXBiotech0.9768 of 5 stars$4.48+1.4%N/A-25.8%$136.56M$4.01M-4.15100Gap UpTSVT2seventy bio2.5292 of 5 stars$2.64-9.3%$9.00+240.9%-36.1%$136.19M$45.62M-1.42440Positive NewsGap UpIFRXInflaRx2.2493 of 5 stars$2.29-5.0%$8.00+249.3%+35.3%$134.84M$168,498.00-2.1260Short Interest ↑News CoverageGap UpLPTXLeap Therapeutics1.8667 of 5 stars$3.36+0.3%$7.50+123.2%-12.0%$128.75M$1.50M-1.7440Positive NewsTELOTelomir PharmaceuticalsN/A$4.23-6.4%N/AN/A$125.25MN/A0.001Short Interest ↑PEPGPepGen2.9534 of 5 stars$3.68-3.9%$13.67+271.4%-60.4%$124.84MN/A-1.2372Short Interest ↓Gap UpMNPRMonopar Therapeutics3.3955 of 5 stars$23.60+2.7%$27.33+15.8%+1,049.6%$124.56MN/A-11.9810Short Interest ↑ Related Companies and Tools Related Companies BMEA Competitors SAVA Competitors NBTX Competitors XBIT Competitors TSVT Competitors IFRX Competitors LPTX Competitors TELO Competitors PEPG Competitors MNPR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GDTC) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GDTC Stock Alerts